New cocktail of three drugs tested for tough bladder cancers
NCT ID NCT01352962
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the safest dose and see how well patients tolerated the treatment. Participants received up to six cycles of the three-drug combo, and some continued lenalidomide alone for up to a year if their cancer did not grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemcitabine, carboplatin, and lenalidomide
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for advanced urothelial cancer and other solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 18 participants, focused on finding the safest dose. The combination may cause severe side effects, and it is unknown whether it will actually shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.